1. Home
  2. LTRN vs INTS Comparison

LTRN vs INTS Comparison

Compare LTRN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LTRN
  • INTS
  • Stock Information
  • Founded
  • LTRN 2013
  • INTS 2012
  • Country
  • LTRN United States
  • INTS United States
  • Employees
  • LTRN N/A
  • INTS N/A
  • Industry
  • LTRN Biotechnology: Pharmaceutical Preparations
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LTRN Health Care
  • INTS Health Care
  • Exchange
  • LTRN Nasdaq
  • INTS Nasdaq
  • Market Cap
  • LTRN 33.7M
  • INTS 33.4M
  • IPO Year
  • LTRN 2020
  • INTS 2023
  • Fundamental
  • Price
  • LTRN $5.08
  • INTS $2.20
  • Analyst Decision
  • LTRN Hold
  • INTS Strong Buy
  • Analyst Count
  • LTRN 1
  • INTS 3
  • Target Price
  • LTRN N/A
  • INTS $8.50
  • AVG Volume (30 Days)
  • LTRN 156.7K
  • INTS 40.1K
  • Earning Date
  • LTRN 03-17-2025
  • INTS 03-13-2025
  • Dividend Yield
  • LTRN N/A
  • INTS N/A
  • EPS Growth
  • LTRN N/A
  • INTS N/A
  • EPS
  • LTRN N/A
  • INTS N/A
  • Revenue
  • LTRN N/A
  • INTS N/A
  • Revenue This Year
  • LTRN N/A
  • INTS N/A
  • Revenue Next Year
  • LTRN N/A
  • INTS N/A
  • P/E Ratio
  • LTRN N/A
  • INTS N/A
  • Revenue Growth
  • LTRN N/A
  • INTS N/A
  • 52 Week Low
  • LTRN $2.79
  • INTS $1.50
  • 52 Week High
  • LTRN $11.99
  • INTS $5.94
  • Technical
  • Relative Strength Index (RSI)
  • LTRN 64.21
  • INTS 54.20
  • Support Level
  • LTRN $4.60
  • INTS $2.00
  • Resistance Level
  • LTRN $5.30
  • INTS $2.37
  • Average True Range (ATR)
  • LTRN 0.61
  • INTS 0.31
  • MACD
  • LTRN 0.06
  • INTS -0.00
  • Stochastic Oscillator
  • LTRN 68.99
  • INTS 48.24

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Share on Social Networks: